Class of Stock [Axis]
Series B Convertible Preferred Stock [Member]
Related and Nonrelated Parties [Axis]
Related Party [Member]
Equity Components [Axis]
Preferred Stock [Member]
Series A Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Business Combination [Axis]
Liora Technologies Europe Ltd [Member]
Debt Instrument [Axis]
Secured Promissory Note [Member]
Ownership [Axis]
Non Controlling Ownership [Member]
Antidilutive Securities [Axis]
Common Stock Warrants [Member]
Common Stock Options [Member]
Segments [Axis]
Single Reportable Segment [Member]
Product and Service [Axis]
Clinical And Related Oversight Costs [Member]
Preclinical Research [Member]
Compound Maintenance [Member]
Regulatory Service Costs [Member]
Geographical [Axis]
UNITED STATES
SPAIN
Investment, Name [Axis]
Undesignated Preferred Stock [Member]
Class of Warrant or Right [Axis]
PreFunded Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Securities Purchase Agreement [Member]
Plan Name [Axis]
February 13, 2025 Equity Offering [Member]
Sale of Stock [Axis]
IPO [Member]
Placement Agents [Member]
Exercise Price Range [Axis]
Exercise Price One [Member]
Exercise Price Two [Member]
Exercise Price Three [Member]
Exercise Price Four [Member]
Exercise Price Five [Member]
Exercise Price Six [Member]
Exercise Price Seven [Member]
Award Type [Axis]
Pre Funded Warrant [Member]
Statistical Measurement [Axis]
Maximum [Member]
Title and Position [Axis]
Mr Pursglove [Member]
Chief Financial Officer [Member]
Employment Agreement [Member]
Mr Stazzone [Member]
BasvanderBaan [Member]
Mr Weingarten [Member]
Dr Jan HM Schellens [Member]
Independent Director [Member]
Board of Directors Chairman [Member]
Restricted Stock Units (RSUs) [Member]
2020 Stock Incentive Plan [Member]
Four Non Officer Director [Member]
Four Non-officer Directors [Member]
Minimum [Member]
Director [Member]
Derivative Instrument [Axis]
Equity Option [Member]
Exercise Price Eight [Member]
Exercise Price Nine [Member]
Exercise Price Ten [Member]
Exercise Price Eleven [Member]
Exercise Price Twelve [Member]
Clinical Trial Agreements and Clinical Trial Monitoring Agreements [Member]
Clinical Trial Agreements [Member]
Clinical Trial Monitoring Agreements [Member]
Other Commitments [Axis]
Phase 1b Two [Member]
Monitoring Agreements [Member]
Legal Entity [Axis]
MD Anderson Cancer Center [Member]
GEIS [Member]
Netherlands Cancer Institute [Member]
Licensing Agreements [Member]
Development Collaboration Agreement [Member]
Collaboration Agreement [Member]
Bio Pharma Works LLC [Member]
MRI Global [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Series D Convertible Preferred Stock [Member]
Merger Agreement [Member]
John Travaglini [Member]
Armistice Capital LLC and Intracoastal Capital LLC [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement [Table]
Statement [Line Items]
ASSETS
Current assets:
Cash
Prepaid insurance
Other prepaid expenses
Note receivable Nomad Transportable Power Systems
Total current assets
LiGHT proton therapy system equipment
Operating lease right-of-use assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses, including $29,258 and $125,959 to related parties
Research and development contract liabilities
Operating lease liabilities, current
Series B Convertible Preferred Stock 8% cumulative dividend payable
Total current liabilities
Operating lease liabilities, long-term
Total liabilities
Commitments and Contingencies
Stockholders’ Equity:
Series B Convertible Preferred Stock, $0.7146 per share stated value – issued and outstanding – none at June 30, 2026 and 2,423,130 as of December 31, 2025
Common stock, $0.0001 par value authorized – 100,000,000 shares; issued and outstanding – 15,417,444 and 8,790,102 shares at June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Total Lixte Biotechnology stockholders’ equity
Non-controlling interest
Total stockholders’ equity
Total liabilities and stockholders’ equity
Related parties accounts payable and accrued expenses
Preferred stock, par value
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues, net
Costs and expenses:
General and administrative costs
Research and development costs
Total costs and expenses
Loss from operations
Other income (expenses):
Interest income
Interest expense
Foreign currency gain (loss)
Net loss
Series B Convertible Preferred Stock 8% cumulative dividend
Non-controlling interest
Net loss attributable to common stockholders
Net loss per common share - basic
Net loss per common share - diluted
Weighted average common shares outstanding basic
Weighted average common shares outstanding diluted
Balance
Balance, shares
Exercise of pre-funded warrants
Exercise of pre-funded warrants, shares
Fair value of Shares issued for services
Fair value of Shares issued for services, shares
Series B Convertible Preferred Stock 8% cumulative dividend
Conversion of Series B Convertible Preferred Stock and related dividend
Conversion of Series B Convertible Preferred Stock and related dividend, shares
Share-based compensation
Stock-based compensation, shares
Net loss
Exercise of common warrants
Exercise of common warrants, shares
Issuance of common stock and pre-funded warrants from public offering, net
Issuance of common stock and pre-funded warrants from public offering, net, shares
Stock-based compensation — vesting of restricted stock units
Stock compensation vesting of restricted stock units, shares
Stock-based compensation — incremental cost related to cancellation of options and issuance of restricted stock units
Stock-based compensation incremental cost related to cancellation of options and issuance of restricted stock units, shares
Cancellation of shares
Cancellation of shares-OPEN, shares
Proceeds from sale of securities registered direct offering, net of offering costs
Proceeds from sale of securities registered direct offering, net of offering costs, shares
Stock options issued to settle accrued payable
Conversion of Series A convertible preferred stock
Conversion of Series A convertible preferred stock, shares
Balance
Balance, shares
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Adjustments to reconcile net loss to net cash used in operating activities:
Change in operating lease right-of-use assets
Stock-based compensation expense
Common stock issued for services
Changes in operating assets and liabilities:
Prepaid insurance
Other prepaid expenses
Accounts payable and accrued expenses
Research and development contract liabilities
Operating lease liabilities
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Capitalized costs LiGHT proton therapy system equipment
Note receivable Nomad Transportable Power Systems
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of securities in registered direct offerings, net of offering costs
Payment of deferred offering costs
Exercise of common stock warrants
Net cash provided by financing activities
NET CHANGE IN CASH
Net increase (decrease)
Cash - Beginning of period
Cash - End of period
Supplemental disclosures of cash flow information:
Cash paid for interest
Non-cash investing and financing activities:
Settlement of accrued compensation to Board of Directors by issuance of stock options
Exercise of pre-funded warrants
Conversion of Series B Convertible Preferred Stock into common stock and related dividend
Conversion of Series A Convertible Preferred Stock into common stock
Accrual of deferred offering costs
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Segment Reporting [Abstract]
Segment Information
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]
Acquisition of Liora Technologies Europe Ltd.
Leases
Leases
Equity [Abstract]
Stockholders’ Equity
Related Party Transactions [Abstract]
Related Party Transactions
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Receivables [Abstract]
Note Receivable NOMAD Transportable Power Systems, Inc
Subsequent Events [Abstract]
Subsequent Events
Use of Estimates
Principles of Consolidation
Cash
Asset Acquisitions
Property and Equipment
Long – Lived Assets
Research and Development
Stock-Based Compensation
Warrants
Segment Information
Earnings (Loss) Per Share
Foreign Currency
Fair Value of Financial Instruments
Recent Accounting Pronouncements
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share
Segment Reporting [Table]
Segment Reporting [Line Items]
Schedule of Information by Segment
Schedule of Supplemental Cash Flow Information Related to Operating Leases
Schedule of Maturities of Operating Lease Liabilities
Schedule of Warrants Outstanding
Schedule of Warrants Outstanding and Exercisable
Summary of Activities Related to Common Stock Warrants
Schedule of Common Stock Warrants and Pre-Funded Warrant
Schedule of Stock-based Compensation Costs
Schedule of Restricted Stock Units
Schedule of Stock Option Activity Including Options Form of Warrants
Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants
Restructuring Cost [Table]
Restructuring Cost and Reserve [Line Items]
Net loss
Net cash used in operations
Contractual commitments
Consideration transferred
Proceeds from direct offering
Secured promissory note
Unrestricted cash
AccountingPoliciesTable [Table]
Acquisition percentage
Noncontrolling interest percentage
Impairment of long lived assets
Number of reportable segment
Foreign currency rate
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total
Total research and development costs
Stock-based compensation
Quarterly board fees
Patent and licensing legal and filing fees costs
Marketing and public relations
Accounting and bookkeeping services
Audit and legal
Consulting fees
Insurance expense
Investment banking
Payroll
Lease
Other costs and expenses, net
Total general and administrative costs
AcquisitionTable [Table]
AcquisitionLineItems [Line Items]
Ownership percentage
Interests acquired
Payments to acquire business
Cash consideration
Digital assets
Digital assets number of units
Stock issued for acquisitions
Stock issued for acquisitions, value
Noncontrolling interest
Capitalized transaction costs
Total cost acquired asset
Consulting expenses
Total cost acquired asset
Capitalized costs
Schedule Of Supplemental Cash Flow Information Related To Operating Leases
Cash payments for operating leases
Weighted average remaining lease terms for operating lease
Weighted average discount rate for operating lease
Schedule Of Maturities Of Operating Lease Liabilities
2026 (remaining)
2027
Thereafter
Total
Less: Imputed interest
Total operating lease liability
Payments for Rent
Operating lease right of use asset
Noncash operating lease cost
Operating lease liability
Accretion of the lease liability
Current portion of operating lease obligation
Long-term portion of operating lease obligation
Lease cost
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares, Warrants Outstanding, Balance
Weighted Average Exercise Price, Warrants Outstanding, Balance per shares
Number of Shares, Issued
Number of Shares, Exercised
Weighted Average Exercise Price, Exercised
Number of Shares, Expired
Weighted Average Exercise Price, Expired
Number of Shares, Warrants Outstanding, Balance
Weighted Average Exercise Price, Warrants Outstanding, Balance per share
Weighted Average Remaining Contractual Life (in Years)
Share-Based Payment Arrangement, Option, Exercise Price Range [Table]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price
Warrants Outstanding Shares
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issued
Exercised
Expired
Common stock warrants
Pre-funded warrants
Total warrants outstanding
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Preferred stock, shares authorized
Preferred stock, dividend rate percentage
Consulting services, shares
Consulting services, values
Stock converted
Cumulative dividends
Common stock dividends shares
Preferred Stock, Shares Outstanding
Warrant holders exercised shares
Shares issued
Share price
Gross proceeds from issuance of shares and warrants
Offering expenses
Warrant exercise price per share
Proceeds from issuance of warrants
Proceeds from sale of securities
Costs of public offering
Net proceeds from issuance of stock
Number of shares issued
Offering price per share
Warrants to purchase of common stock
Warrant expires date
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Annual salary
Compensation
Total cash compensation
Fair value of vested options
Incremental cost related to cancellation of options and issuance of restricted stock units
Fair value of vested RSUs
Non-related parties
Total stock-based compensation costs
Number of RSUs, Non-vested, Beginning Balance
Weighted Average Grant Date Fair Value, Non-vested, Beginning Balance
Number of RSUs, Granted
Weighted Average Grant Date Fair Value, Granted
Number of RSUs, Vested
Weighted Average Grant Date Fair Value, Vested
Number of RSUs, Forfeited
Weighted Average Grant Date Fair Value, Forfeited
Number of RSUs, Non-vested, Ending Balance
Weighted Average Grant Date Fair Value, Non-vested, Ending Balance
Number of shares, stock options outstanding, beginning
Weighted average exercise price, stock options outstanding, beginning
Number of shares, granted
Weighted average exercise price, granted
Number of shares, Cancelled
Weighted average exercise price, cancelled
Number of shares, expired
Weighted average exercise price, expired
Number of shares, stock options outstanding, ending
Weighted average exercise price, stock options outstanding, ending
Weighted average remaining contractual life (in years), stock options outstanding
Number of shares, stock options exercisable at the beginning
Weighted average exercise price, stock options exercisable
Weighted average remaining contractual life (in years), stock options exercisable
Exercise Prices
Options Outstanding (Shares)
Options Exercisable (Shares)
Stock options granted
Fair value
Stock options granted value
Compensation expense
New shares issued
Vested upon grant
Fair value of stock options
Fair value of vested
Unamortized stock compensation expense
Shares outstanding
Shares were available for issuance
Stock option vested exercisable term
Exercise price
Fair value of stock options
Accrued fair value of stock options
Stock based compensation
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares
Fair market value per share
Unexercised common stock options
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Contractual obligation
Funding obligation
Aggregate commitments expected
Minimum annual royalty payable
Royalty description
Contingent milestone payments
Research and development process costs
Other commitment remaining term
Reimbursed expense
Advance amount related to milestone payment
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Proceeds from Sale and Collection of Notes Receivable
Debt Instrument, Interest Rate During Period
Financing Receivable, after Allowance for Credit Loss, Current
Debt Instrument, Face Amount
Subsequent Event [Table]
Shares conversion of units
Shares Issued, Price Per Share
Working capital
Note receivable
Repayments of debts
Compensation committee granted
Common Stock, Capital Shares Reserved for Future Issuance
Outstanding common warrant shares
Warrants and rights outstanding shares
Warrants and rights outstanding
Cash settlement
Class of Warrant or Right, Exercise Price of Warrants or Rights
Class of Warrant or Right, Outstanding
Research and development contract liabilities current.
Series B Convertible Preferred Stock cumulative dividend payable.
Series B Convertible Preferred Stock [Member]
Preferred stock dividends and other adjustment.
Series A Convertible Preferred Stock [Member]
Issuance of common stock and pre-funed warrants from public offering, net.
Stock issued during period shares issuance of common stock and pre-funed warrants from public offering net shares.
Stock issued during period value proceeds from sale of securities in december registered direct offering net of offering costs.
Stock issued during period shares proceeds from sale of securities in december registered direct offering net of offering costs.
Non-cash operating lease cost.
Increase decrease in research and development contract liabilities
Payments for capitalized transaction costs.
Settlement of accrued compensation to board of directors by issuance of stock options.
Exercise of pre-funded warrants.
Conversion of series b convertible preferred stock into common stock and related dividend.
Conversion of series convertible preferred stock into common stock.
Accrual of deferred offering costs.
Non-cash amortization of right-of-use asset and liabilities.
Liora Technologies Europe Ltd [Member]
Asset Acquisition [Policy Text Block]
Warrants [Policy Text Block]
Foreign currency exchange rate translation.
Compound Maintenance [Member]
Legal fees relating to patents and licensing.
Accounting and bookkepping services
Audit and legal
Consulting fees
Payroll expense.
Lease expenses.
Consulting expenses.
Secured Promissory Note [Member]
Lessee operating lease liability payments due after year three.
Preferred stock, shares eliminate.
Undesignated Preferred Stock [Member]
Consulting Agreement [Member]
Pillow Hog Ventures Inc [Member]
PreFunded Warrants [Member]
Securities Purchase Agreement [Member]
Offering expenses.
February Thirteen Twenty and Twenty Five Equity Offering [Member]
Placement Agents [Member]
Common Stock Warrants [Member]
Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.
Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price.
Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price.
Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Schedule Of Warrants Outstanding And Exercisable [Table Text Block]
Exercise Price One [Member]
Exercise Price Two [Member]
Exercise Price Three [Member]
Exercise Price Four [Member]
Exercise Price Five [Member]
Exercise Price Six [Member]
Exercise Price Seven [Member]
Pre Funded Warrant [Member]
Pre Funded Warrant [Member]
Schedule Of Common Stock Warrants And Pre Funded Warrant [Table Text Block]
Common stock warrants.
Prefunded warrants.
Mr Pursglove [Member]
Employment Agreement [Member]
Mr Stazzone [Member]
BasvanderBaan [Member]
Mr Weingarten [Member]
Independent Director [Member]
2020 Stock Incentive Plan [Member]
Four Non Officer Director [Member]
Four Non-officer Directors [Member]
Fair value of stock options.
Geordan Pursglove [Member]
Peter Stazzone [Member]
Michael Holloway [Member]
Guy Primus [Member]
Lourdes Felix [Member]
Jason Sawyer [Member]
Exercise Price Eight [Member]
Exercise Price Nine [Member]
Exercise Price Ten [Member]
Exercise Price Eleven [Member]
Exercise Price Twelve [Member]
Unexercised common stock options.
Clinical Trial Agreements And Clinical Trial Monitoring Agreements [Member]
Clinical Trial Agreements [Member]
Clinical Trial Monitoring Agreements [Member]
Phase 1b Two [Member]
Funding obligation.
Monitoring Agreements [Member]
Netherlands Cancer Institute [Member]
MD Anderson Cancer Center [Member]
Spanish Sarcoma Group [Member]
Royalty payable.
Contingent milestone payments.
Royalty description.
Other commitment term.
Reimbursement expense.
Collaboration Agreement [Member]
Bio Pharma Works LLC [Member]
Advance amount related to milestone payment.
MRI Global [Member]
Development Collaboration Agreement [Member]
Series D Convertible Preferred Stock [Member]
Common Stock Options [Member]
Clinical And Related Oversight Costs [Member]
Preclinical Research [Member]
Regulatory Service Costs [Member]
Proceeds from sale and collection of note receivable.
Quarterly board fees.
Unrestricted cash.
Non Controlling Ownership [Member]
Single Reportable Segment [Member]
Dr Jan HM Schellens [Member]
John Travaglini [Member]
Armistice Capital LLC and Intracoastal Capital LLC [Member]
Outstanding common warrant shares
Capitalized costs LiGHT proton therapy system equipment.
Accrued fair value of stock options
Working capital.
Merger Agreement [Member]
Assets, Current
Assets
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Equity, Including Portion Attributable to Noncontrolling Interest
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Interest Expense, Operating and Nonoperating
Net Income (Loss) Attributable to Noncontrolling Interest
Net Income (Loss) Available to Common Stockholders, Basic
Shares, Outstanding
Adjustments to Additional Paid in Capital, Other
Shares Issued, Value, Share-Based Payment Arrangement, Forfeited
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited
Increase (Decrease) in Prepaid Insurance
Increase (Decrease) in Prepaid Expenses, Other
IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
ProceedsFromSaleAndCollectionOfNoteReceivable
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Payments of Financing Costs
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
ExerciseOfPrefundedWarrants
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Lessee, Operating Leases [Text Block]
Commitments and Contingencies Disclosure [Text Block]
Cash and Cash Equivalents, Policy [Policy Text Block]
Share-Based Payment Arrangement [Policy Text Block]
Segment Reporting, Policy [Policy Text Block]
Other General and Administrative Expense
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Fair value of stock options [Default Label]
WorkingCapital